3 results
Induction PeriodPrimary:Demonstrate the efficacy of RPC1063 versus placebo on induction of clinical remission.Secondary:* Demonstrate the efficacy of RPC1063 versus placebo on induction of clinical response* Demonstrate the efficacy of RPC1063…
Primary Objectives:Safety Run-in PartTo establish a safe and tolerable dose of azacitidine to be used in the randomized part of thestudy.Randomized PartTo evaluate the effect of azacitidine treatment in AML subjects at molecular relapse after…
The purpose of this study is to assess whether a new combination treatment (Savolitinib and Durvalumab) is better than standard treatment sunitinib in MET-driven PRCC. The study will also assess the contribution of one part of the combination (…